Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 14/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12932877 | 0.86 | HRH4 (0.50) | HRH4HRH3NUDT1SYK | |
| SCHEMBL15181300 | 0.81 | SYK (0.44) | HRH4HRH3SYK | |
| SCHEMBL14029983 | 0.80 | HRH4 (0.54) | HRH4HRH3NUDT1CHRNA7 | |
| SCHEMBL15181297 | 0.79 | HRH4 (0.51) | HRH4SYK | |
| SCHEMBL9169741 | 0.79 | HRH4 (0.52) | HRH4HRH3NUDT1CHRNA7 | |
| SCHEMBL11988199 | 0.78 | HRH4 (0.52) | HRH4SYK | |
| SCHEMBL84157 | 0.77 | SYK (0.50) | SYK | |
| SCHEMBL24650717 | 0.77 | MKNK1 (0.48) | SYK | |
| SCHEMBL14004971 | 0.76 | HRH4 (0.50) | HRH4HRH3NUDT1CHRNA7PIK3CD | |
| SCHEMBL12933710 | 0.76 | HRH4 (0.50) | HRH4HRH3NUDT1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932354-B2 | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | ARES TRADING S.A. (CH) | 2018-04-03 | — | — | US | disclosed |
| US-20150175628-A1 | IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175628-A1 | IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES | APP, BACE1, PSEN1 | HRH4 1927/4885HRH3 2402/4885NUDT1 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.